Speeding Up Safety: An Evaluation Of Mycoplasma Technology

Cell and gene therapies are transforming modern medicine, but their complexity introduces unique challenges in ensuring product safety and timely patient delivery. One critical concern is mycoplasma contamination, which can compromise therapeutic integrity and pose serious risks to patients. Traditional testing methods, while reliable, often require large sample volumes and prolonged turnaround times of up to several weeks—creating bottlenecks in manufacturing and delaying treatment.

Advances in molecular testing technologies offer a solution by enabling faster, more efficient detection with minimal hands-on effort and smaller sample requirements. These approaches integrate automated workflows and sensitive detection mechanisms to identify contamination at low levels across a variety of materials, including raw inputs and final products.

By accelerating detection timelines while maintaining regulatory compliance and analytical rigor, rapid testing methods help streamline manufacturing workflows, support quicker product release, and ultimately improve patient access to critical therapies.